IPD.AX

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Medical - Devices

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$20M	+29.4%	$-0.00	$-0.00–$-0.00	—	4
2028	$27M	+35.7%	$-0.00	$-0.00–$-0.00	—	3
2029	$34M	+28.9%	$-0.00	$-0.00–$-0.00	—	2

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 6 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-27	$-0.00	$-0.01	-497.9%
2026-02-25	$-0.00	$-0.01	-200.0%
2025-07-31	$-0.00	$-0.01	-100.0%
2025-02-25	$-0.01	$-0.00	+88.0%
2024-08-28	$-0.01	$-0.01	+16.7%
2024-02-26	$-0.01	$-0.01	+0.0%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
IPD.AXImpediMed Limited	$0.01	+0.00%	$10M	—
ATX.AXAmplia Therapeutics Limited	$0.12	+0.00%	$62M	—
CMP.AXCompumedics Limited	$0.28	+0.00%	$55M	—
CYC.AXCyclopharm Limited	$0.50	-7.41%	$63M	—
EYE.AXNova Eye Medical Limited	$0.13	-3.70%

ImpediMed Limited

Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.

www.impedimed.com

Employees: 66
IPO / List date: Oct 24, 2007
HQ: US

Held by traders on TradeandTell

No one on the platform currently holds IPD.AX.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in IPD.AX as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded IPD.AX yet.